Trials / Completed
CompletedNCT05227404
Evaluation of Point-of-Care (EPOC) for COVID-19
Evaluation of the Feasibility and Reproducibility of 2 Point-of-Care Tests for SARS-Co-V-2 Antibodies (INSIGHT 017)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 330 (actual)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | LumiraDX | Point-of-care test for SARS-CoV-2 |
| DIAGNOSTIC_TEST | RightSign | Point-of-care test for SARS-CoV-2 |
| DIAGNOSTIC_TEST | Case Control | Genscript assay performed on the plasma sample |
Timeline
- Start date
- 2022-04-08
- Primary completion
- 2022-09-02
- Completion
- 2022-09-02
- First posted
- 2022-02-07
- Last updated
- 2024-12-06
- Results posted
- 2024-12-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05227404. Inclusion in this directory is not an endorsement.